Guest View
User: Pass: | become a member
Posts Tagged ‘pharmaceuticals’

Generic Drug Makers

Here’s another terrific post by Pharmboy, this time discussing Generic Drug Makers. - Ilene

Generic Drug Makers

Variety of Pills

Courtesy of Pharmboy

Coming to the end of a good year, and good riddance for some!  Whilst the market has been irrational for some time, it is not about what we think but rather about what others that have money think.  I have my notions, and here are a few companies that may do well in the New Year with a passed health care reform bill.

I really like the generic market right now. With patents expiring you can literally gauge how much a generic will make based on the patents expiring in the next few months. These generics are the vultures that follow the in a pack of lions.  They have a good way of scavenging for their food and vultures have a distinct relationship with the lions.  They may not come up with the drugs but they are definitely going to make a nice margin from them.  But the competition is fierce these days, and competitors in the generic market include Watson (WPI), Teva (TEVA) , Dr Reddy’s Labs (RDY), Hi-Tech Pharmacal (HITK), Par Pharmaceuticals (PRX), and Caraco (CPD).

First up, Mylan Pharmaceuticals (MYL) - I know that Phil has liked Teva in the past and I have noted Mylan (#3 in generics), WPI and RDY (pre-GSK rumors).  Currently, Mylan has blown through its 52 week high so is it still a buy?  In short answer, yes.  Mylan’s future comes from a swath of FDA approvals that have come in over the past few months.

  1. August 27, 2009 Mylan Begins Marketing First Generic Version of BenzaClin(R) Acne Treatment
  2. August 18, 2009 Mylan’s Matrix Receives First and Only Tentative FDA Approval Under PEPFAR for Generic Version of Atripla(R) HIV Treatment
  3. August 10, 2009 Mylan Receives FDA Approval for Generic Version of Migraine Treatment Imitrex(R)
  4. July 20, 2009 Mylan Receives FDA Approval for Additional Strengths of the Antipsychotic Haloperidol— Key News from the article. Currently, Mylan has 119 ANDAs pending FDA approval representing $84.7 billion in annual brand sales, according to IMS Health. Thirty-five of these pending ANDAs are potential first-to-file opportunities, representing $16.6 billion in annual brand sales, according to IMS Health.
  5. July 16, 2009 Mylan Receives FDA Approval for Generic Version of Thyroid Deficiency Treatment Cytomel
  6. July 7, 2009 Mylan Receives FDA Approval for Generic Version of Prostate Cancer Treatment Casodex
  7. June 17, 2009 Mylan Receives FDA Approval for Additional Strength of Generic…
    continue reading

Tags: , , , , ,



Obama’s Backroom Healthcare Deals Need Explaining

Obama’s Backroom Healthcare Deals Need Explaining

Courtesy of Mish

With $900 billion to a $trillion dollars or more at stake, and everyone wanting three shares of the health care pie (while giving up nothing), it should not come as a surprise that ‘Special interests’ play both sides in health fight

"We have the American Nurses Association, we have the American Medical Association on board," Obama told the weekend crowd in Grand Junction, Colo. "We have an agreement from drug companies to make prescription drugs more affordable for seniors. … The AARP supports this policy."

The drug makers went first in making a deal with the White House, agreeing to pick up $80 billion in additional costs over the next decade to help defray the expenses of the legislation. The American Hospital Association agreed to shoulder an additional $155 billion.

In exchange, both won assurances the White House would protect them against attempts in Congress to seek additional cuts in their projected Medicare and Medicaid payments.

The American Medical Association’s key issue was different. Doctors hope the legislation will allow them to avoid a looming 21 percent cut in payments under Medicare. The cost to the government for that would be about $230 billion over a decade.

Obama also agreed to require individuals to purchase insurance, reversing a position he held during his campaign. "My thinking on the issue of mandates has evolved. And I think that that is typical of most people who study this problem deeper," he said.

Health Care Sweeteners

It’s easy to get buy-ins when you give away the farm. Obama brags about the buy-ins but does not state the costs. Pharmaceutical manufacturers certainly smell the gravy train as noted in Drugmakers Ramp Advertising Campaign For Health Care Reform.

The more promotion there is for this package the more leery of it you should be. The reason the AMA, AARP, and now PhRMA are all lining up behind healthcare reform is because everyone of them has been bought out by sweeteners.

While everyone is concerned about rationing, I am concerned about lack of rationing. What incentives does anyone have to hold down costs?

Certainly big PhRMA has to be thinking more drugs will be prescribed or they would not have a huge ad campaign going while pledging $80 billion in lower drug costs. Here are two key questions: Is it really $80 billion? And what did the Administration give up in return?

Huge Giveaways In White House Deal With Big…
continue reading


Tags: , , ,



 

Zero Hedge

Why is the President's Working Group Oppossing the FDIC Reform Proposals on Residential Mortgage Securitization by Banks?

Courtesy of rc whalen

This week in The IRA we feature a conversation with Bill King, who along with his wife and business partner Mary works in the world of derivatives broadly defined via their Chicago-based firm, M. Ramsey King Securities. We first started taking with Bill in the 1980s, during the political wrangle - we won't call it a battle - over free trade with and democracy in Mexico. That was about the time of the first appearance of "Too Big to Fail" for the large banks following the Mexican peso meltdown. Un fuerte abrazo a nuestros amigos en Mexico!

But before we go to our feature, a few comments on current events. First and foremost we remind one and all about the impending start of the FDIC's rule make effort regarding the reform of bank securitizations. Last week, the FDIC approved an extension through September 30, 2010 of the more from Tyler

Chart School

Stock Market Commentary: New Highs for Tech and Small Caps

Stock Market Commentary: New Highs for Tech and Small Caps

Courtesy of Fallond Stock Picks 

Small Caps and Tech continued their good form. Technicals continue to support the move higher for Small Caps (Russell 2000) with new highs for the MACD and +DI line. The Russell 2000 would have to give up 25 points (or 4%) just to test breakout support at 650.

The prior underperformance of the semiconductors was undone with today's 2% gain. 

more from Chart School

Trading Goddess

"Flow" like Water...

In his ground breaking work FLOW (Mihaly Csikszentmihalyi), a psychology professor at the University of Chicago, interviewed thousands of people to discover the characteristics and qualities of the ideal performance state. He termed this state “FLOW”. It is a unified experience of heightened focus and “flowering” (his term) in the moment where we feel total confidence and control.
Characteristics of Flow:

Physical Relaxation

Psychological Calm

Optimism

Energised Demeanour

Active Engagement

Loving Fun

Managed Anxiety

Effortlessness

Automatic Responses

Alertness

Confidence

In Control

Focus

As you think about the ideal performance state, see how it relates to your own trading. Ask yourself the following questions:

1. When you trade, do you feel relaxed and loose?

2. Do you feel a sense of ...

more from Goddess

The Options Report

By Andrew Wilkinson


Options Player Reveals Long-Term Bullish Sentiment on AIG

Today’s tickers: AIG, MU, F, POT, CLF, PAYX, ERIC, SVU, LFC & CA

AIG - American International Group, Inc. – The insurer’s shares experienced a fantastic 56.7% run up from its low point in the current month of $24.54 on March 3, 2010, up to yesterday’s intraday high of $38.45. During the current session, AIG surrendered a small portion of its recent share price gains, slipping slightly lower by 1.40% to stand at $34.62 in afternoon trading. Extreme-bullish positioning in long-dated options caught our attention today as one investor established a call spread in the January 2011 contract. The optimistic trader purchased 5,500 calls at the January 2011 $50 strike for a premium of $3.65 apiece, and sold the same number of calls at the higher January 2011 $75 strike for $1.30 each. The net cost of the transaction, an...



more from Andrew

Insider Zone


INSIDER SELLING HITS NEW 2010 HIGH

Update on insider activity from Pragcap -- selling still far exceeds buying, confirming my thoughts on Feb. 20 that trends haven't changed. - Ilene 

INSIDER SELLING HITS NEW 2010 HIGH

Courtesy of The Pragmatic Capitalist 

The recent uptick in stocks has not been met with much enthusiasm by corporate insiders.  In fact, pessimism rules the day in the land of insider buying and selling trends.  For the week ending February 26th insiders sold a total of $1.88...


http://www.insidercow.com/ more from Insider

OpTrader


Swing trading portfolio - Week of March 8th, 2010

This post is for live trades and daily comments. 

To learn more about the swing trading portfolio (strategy, membership etc.), please click here

- Optrader

...

more from OpTrader


March 2010
M T W T F S S
« Feb «-»  
1234567
891011121314
15161718192021
22232425262728
293031  

Locations of visitors to this page

FeedTheBull - Top Stock market and Finance Sites

As Seen On:




About Phil:

Philip R. Davis is a founder Phil's Stock World, a stock and options trading site that teaches the art of options trading to newcomers and devises advanced strategies for expert traders...

Learn more About Phil >>

About Ilene:

Ilene is editor and affiliate program coordinator for PSW. She manages the Favorites backup site (blogroll, archives, more). Contact Ilene to learn about our affiliate and content sharing programs.

Favorites Site >>